|
1
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2008. National Cancer
Institute; Bethesda, MD: 2011, http://seer.cancer.gov/csr/1975_2008/
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu Y, Yang XQ, Han CT, Dai B, Zhang HL,
Shi GH, Wang CF and Ye DW: Pathological features of localized
prostate cancer in China: A contemporary analysis of radical
prostatectomy specimens. PLoS One. 10:e01210762015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garg M, Dalela D, Goel A, Kumar M and
Sankhwar SN: Prevention of prostate cancer with vitamins - current
perspectives. Asian Pac J Cancer Prev. 15:1897–1904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Euling SY and Kimmel CA: Developmental
stage sensitivity and mode of action information for androgen
agonists and antagonists. Sci Total Environ. 274:103–113. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bickers B and Aukim-Hastie C: New
molecular biomarkers for the prognosis and management of prostate
cancer - the post PSA era. Anticancer Res. 29:3289–3298.
2009.PubMed/NCBI
|
|
7
|
Siddiqui E, Mumtaz FH and Gelister J:
Understanding prostate cancer. J R Soc Promot Health. 124:219–221.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hudson RS, Yi M, Esposito D, Watkins SK,
Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB,
et al: MicroRNA-1 is a candidate tumor suppressor and prognostic
marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hailer A, Grunewald TG, Orth M, Reiss C,
Kneitz B, Spahn M and Butt E: Loss of tumor suppressor mir-203
mediates overexpression of LIM and SH3 protein 1 (LASP1) in
high-risk prostate cancer thereby increasing cell proliferation and
migration. Oncotarget. 5:4144–4153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viticchiè G, Lena AM, Latina A, Formosa A,
Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli
LG, et al: MiR-203 controls proliferation, migration and invasive
potential of prostate cancer cell lines. Cell Cycle. 10:1121–1131.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chew CS, Chen X, Parente JA Jr, Tarrer S,
Okamoto C and Qin HY: Lasp-1 binds to non-muscle F-actin in vitro
and is localized within multiple sites of dynamic actin assembly in
vivo. J Cell Sci. 115:4787–4799. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakagawa H, Terasaki AG, Suzuki H, Ohashi
K and Miyamoto S: Short-term retention of actin filament binding
proteins on lamellipodial actin bundles. FEBS Lett. 580:3223–3228.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grunewald TG, Kammerer U, Schulze E,
Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1
influences zyxin localization, inhibits proliferation and reduces
migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang
S, Sun X, Li J, Deng Y, Jiang Y, et al: Promotion of colorectal
cancer growth and metastasis by the LIM and SH3 domain protein 1.
Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salvi A, Bongarzone I, Miccichè F, Arici
B, Barlati S and De Petro G: Proteomic identification of LASP-1
down-regulation after RNAi urokinase silencing in human
hepatocellular carcinoma cells. Neoplasia. 11:207–219. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Li W, Jin X, Cui S and Zhao L: LIM
and SH3 protein 1, a promoter of cell proliferation and migration,
is a novel independent prognostic indicator in hepatocellular
carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyamoto S and Verma IM: Rel/NF-kappa B/I
kappa B story. Adv Cancer Res. 66:255–292. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bargou RC, Emmerich F, Krappmann D,
Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A,
Scheidereit C, et al: Constitutive nuclear factor-kappaB-RelA
activation is required for proliferation and survival of Hodgkin's
disease tumor cells. J Clin Invest. 100:2961–2969. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS,
Kim Y, Han SB, Oh KW and Hong JT: Inhibition of NF-kappaB by
ginsenoside Rg3 enhances the susceptibility of colon cancer cells
to docetaxel. Arch Pharm Res. 32:755–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suh J, Payvandi F, Edelstein LC, Amenta
PS, Zong WX, Gélinas C and Rabson AB: Mechanisms of constitutive
NF-kappaB activation in human prostate cancer cells. Prostate.
52:183–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herrmann JL, Beham AW, Sarkiss M, Chiao
PJ, Rands MT, Bruckheimer EM, Brisbay S and McDonnell TJ: Bcl-2
suppresses apoptosis resulting from disruption of the NF-κB
survival pathway. Exp Cell Res. 237:101–109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Butt E, Gambaryan S, Göttfert N, Galler A,
Marcus K and Meyer HE: Actin binding of human LIM and SH3 protein
is regulated by cGMP- and cAMP-dependent protein kinase
phosphorylation on serine 146. J Biol Chem. 278:15601–15607. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li B, Zhuang L and Trueb B: Zyxin
interacts with the SH3 domains of the cytoskeletal proteins
LIM-nebulette and Lasp-1. J Biol Chem. 279:20401–20410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schreiber V, Moog-Lutz C, Régnier CH,
Chenard MP, Boeuf H, Vonesch JL, Tomasetto C and Rio MC: Lasp-1, a
novel type of actin-binding protein accumulating in cell membrane
extensions. Mol Med. 4:675–687. 1998.PubMed/NCBI
|
|
28
|
Mattson MP: NF-kappaB in the survival and
plasticity of neurons. Neurochem Res. 30:883–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Ellis KL, Ali S, El-Rayes BF,
Nedeljkovic-Kurepa A, Kucuk O, Philip PA and Sarkar FH:
Apoptosis-inducing effect of chemotherapeutic agents is potentiated
by soy isoflavone genistein, a natural inhibitor of NF-kappaB in
BxPC-3 pancreatic cancer cell line. Pancreas. 28:e90–e95. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qin Z-H, Wang Y, Nakai M and Chase TN:
Nuclear factor-κ B contributes to excitotoxin-induced apoptosis in
rat striatum. Mol Pharmacol. 53:33–42. 1998.PubMed/NCBI
|
|
31
|
Beg AA and Baltimore D: An essential role
for NF-kappaB in preventing TNF-alpha-induced cell death. Science.
274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI
|
